Melbourne EpiCentre

Research Overview

The Melbourne EpiCentre is a collaborative research centre of the University of Melbourne and Melbourne Health embedded within the Royal Melbourne Hospital. It is an academic centre of excellence with research, education, health care quality and safety, and organisation-improvement agenda.

Melbourne EpiCentre is a National Collaborative Research Infrastructure Strategy (NCRIS) funded facility, with expertise in the planning, design, data management, statistical and clinical reporting of clinical trials, conforming to FDA requirements and industry standards.

The EpiCentre is leading several early and late phase clinical trials and clinical epidemiological projects with large primary and ambulatory care databases from the US and UK. The EpiCentre also provides study design, data management and biostatistical support for diverse research groups across the University and Melbourne Health, as well as providing analytical support for data relating to health care services quality and safety.

The Centre's key research areas are:

  1. Clinical trials
  2. Clinical epidemiology research
  3. Health services research
  4. Methodological research

Staff

Associate Staff

Collaborators

AUSTRALIAN COLLABORATORS:

  • Therapeutic Innovation Australia – Queensland Node
  • Melbourne Ageing Research Collaboration (MARC)
  • Department of Health and Human Services, Victoria
  • National Ageing Research Institute (NARI)
  • Burns, Trauma and Critical Care Research Centre, University of Queensland
  • Centre for Clinical Research, University of Queensland
  • Centre for Research in Geriatric Medicine, University of Queensland
  • Diamantina Institute, University of Queensland
  • School of Health and Rehabilitation Sciences, University of Queensland
  • School of Allied Health Sciences, Griffith University
  • Baker IDI Heart & Diabetes Institute, Melbourne
  • OzStar Therapeutics Pty Ltd
  • Diabetes and Endocrinology Department, Princess Alexandra Hospital, Queensland Health
  • Bone Marrow Transplant Laboratory

INTERNATIONAL:

  • Imperial College London, UK
  • University of Oxford, UK
  • University of Leicester, UK
  • University of North Carolina, USA
  • University of Minnesota, USA
  • Bristol-Myers Squibb: Amylin Pharmaceuticals, USA
  • Genentech
  • Medtronic
  • Novo Nordisk A/S, Denmark
  • AstraZeneca
  • Chinese Academy of Sciences, China
  • Peking University, China
  • Guangzhou Zhongyi Pharmaceutical Co. Ltd., China
  • Agilent Technologies Inc., USA

Funding

  • Paul S. Translating Health Discovery (THD) NCRIS 2016 Funding Program, 2016-17.
  • Paul S. Effect of weight change and its interactions with glycaemic control and blood pressure on cardiovascular and mortality risks in patients with type 2 diabetes – A Part of Programme of Clinical Epidemiological Studies. AstraZeneca Investigator Initiated Research Grant. 2016-18.
  • Roberts JR, Lipman J, Peake S, Turnidge J, Slavin M, Hopkins P, Bulitta J, Paul S (Chief Investigator), de Waele J, Joynt G. Centre for Redefining antibiotic use to reduce resistance and prolong the lives of antibiotics (REDUCE). NHMRC Centre of Research Excellence, 2016-20.
  • Beck B, Rubin C, Paul S (Chief Investigator), Forwood M. Whole body vibration for osteoporosis: Shaking up our treatment options. NHMRC Project Grant, 2015-19.
  • Paul S, Atherton J. Evaluation of the association of old and new anti-diabetes drugs with the risk of heart failure in patients with type 2 diabetes. RBWH Foundation, 2016-17.
  • Paul S (Lead Chief Investigator), Shaw J, Majeed A, Khunti K, Klein K. Evaluation of the obesity paradox in diabetes: A longitudinal case-control study of half a million patients. NHMRC Project Grant, 2014-17.
  • Roberts JA, Lipman J, Peake S, Roberts MS, Paul S (Chief Investigator), Turnidge J.  Robust antibiotic dosing for critically ill patients receiving renal replacement therapy. NHMRC Project
  • Grant (Roberts J et al.), 2013-16.
  • Paul S (Principal Statistician / Investigator). Telehealth in residential aged care facilities: a pragmatic randomized control trial. NHMRC Project Grant (Gray L et al.), 2013-17.
  • The Dementia Care Pathway for use in acute hospitals: development, implementation and evaluation funded by the Victorian Department of Health & Melbourne Health $330,000. Commenced 1/2014.
  • Strategies for Relatives (START) Online. State Trustees and MARC funded $60,000. Commenced 7/2016.
  • Preventing Avoidable Hospital Admissions for People with Dementia. State Trustees and MARC funded $60,000. Commenced 5/2016.

Research Publications

For a complete list of Prof Sanjoy Paul's publications click here.

5 recent Melbourne EpiCentre publications:

  1. Paul SK, Owusu Adjah ES, Samanta M, Patel K, Bellary S, Hanif W, et al. Comparison of body mass index at diagnosis of diabetes in a multi-ethnic population: A case-control study with matched non-diabetic controls. Diabetes, Obesity & Metabolism. 2017.
  2. Tropea J, LoGiudice D, Liew D, Gorelik A, Brand C. Poorer outcomes and greater healthcare costs for hospitalised older people with dementia and delirium: a retrospective cohort study. International Journal of Geriatric Psychiatry. 2017;32(5):539-47.
  3. Montvida O, Klein K, Kumar S, Khunti K, Paul SK. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes, obesity & metabolism. 2017;19(1):108-17.
  4. Tropea J, LoGiudice D, Liew D, Roberts C, Brand C. Caring for people with dementia in hospital: findings from a survey to identify barriers and facilitators to implementing best practice dementia care. International Psychogeriatrics. 2016:1-8.
  5. Paul SK, Shaw JE, Montvida O, Klein K. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes. Diabetes, obesity & metabolism. 2016;18(12):1244-52.